



UNIVERSITY OF LEEDS

This is a repository copy of *Covid-19: An urgent call for global “vaccines-plus” action*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/189273/>

Version: Accepted Version

Article:

An open letter by a group of public health experts, clinicians, (2022) Covid-19: An urgent call for global “vaccines-plus” action. *BMJ*, 376. o1. ISSN 1759-2151

<https://doi.org/10.1136/bmj.o1>

© 2022, BMJ Publishing Group Ltd. This manuscript version is made available under the CC BY-NC 4.0 license <https://creativecommons.org/licenses/by-nc/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Covid-19: An urgent call for global ‘vaccines-plus’ action

SARS-CoV-2 has infected more than 278 million people globally, with at least 5.4 million deaths recorded by the World Health Organization as of 26 December 2021. The Omicron (B.1.1.529) variant of concern is spreading rapidly.[1]

Some countries view infection as a net harm and pursue strategies ranging from suppression to elimination.[2] They seek to sustain low infection rates through a combination of vaccination, public health and financial support measures (vaccines-plus). Other countries implemented mitigation strategies that aim to prevent health systems from being overwhelmed by building population immunity through a combination of infection and vaccination. These countries rely on a vaccines-only approach and seem willing to tolerate high levels of infection provided their healthcare systems can cope.

The high transmissibility and degree of immune escape by the Delta and Omicron variants means sustained protective population immunity is unlikely to be achieved with the current vaccines based on the original strain.[3] Compared to Delta, Omicron is much more likely to infect those who were vaccinated or exposed to previous SARS-CoV-2 variants, suggesting significant immune escape.[4]

Widespread transmission brings a degree of unpredictability to the pandemic response. High transmission risks more rapid adaptation of SARS-CoV-2, with outcomes that include increased transmissibility (seen with Alpha, Delta and Omicron), increased antibody immune escape (Beta and Omicron) or greater pathogenicity (Delta and Alpha).[5]

There are other drawbacks to a vaccines-only strategy. Countries which tolerated high transmission have seen rises in both COVID-specific and all-cause mortality, healthcare worker shortages and repeated lockdowns to control surges in case numbers. [2,6-9] Countries which suppressed transmission early saw reduced mortality and less economic damage.[2, 7, 10, 11]

While vaccination greatly reduces risks of serious illness and death, Long COVID remains a concern.[12,13] Disruption to education as a result of staff and student sickness, and/or repeated lockdowns due to failure to control the virus, are likely to have a lasting impact on the wellbeing and prospects of the next generation.[14]

High levels of transmission also create a negative feedback loop, whereby important public health measures such as test, trace, isolate and support systems become overwhelmed, making them less effective, further fuelling transmission.[15]

For all these reasons, a vaccines-plus approach should be adopted globally. This strategy will slow the emergence of new variants and ensure they exist in a low transmission background where they can be controlled by effective public health measures, while allowing everyone (including those clinically vulnerable) to go about their lives more freely.

We welcome the World Health Organization's recent guidance on community[16] and healthcare[17] mask use, but believe more can be done to suppress transmission without adversely impacting economic or social activity. Accordingly, we call upon the World Health Organization and national governments to:

1. Unequivocally declare SARS-CoV-2 an airborne pathogen and stress the implications for preventing transmission.[18] A clear message from the World Health Organization will help to remove confusion that has been used to justify outdated policies.[19]
2. Promote the use of high-quality face masks for indoor gatherings and other high-transmission settings. The significant benefits of community masking are now well-established.[20,21] Respirators (e.g. N95, P2/FFP2 or KF94) should be preferred in all indoor settings where people mix, and for healthcare workers at all times.[21,22]
3. Advise on effective ventilation and filtration of air. It is time to go beyond opening windows and aim for a paradigm shift to ensure all public buildings are optimally designed, built, adapted and utilised to maximise clean air for occupants — strategies which have been shown to reduce SARS-CoV-2 transmission.[23 - 25]

4. Set criteria for imposing or relaxing measures to reduce COVID-19 spread based on levels of transmission in the community. Effective find, test, trace, isolate and support will continue to be essential to intercept transmission. Low rates of transmission give all available measures the best chance of being effective, creating a positive, self-reinforcing cycle of disease control. Sufficient financial and practical support for isolation should be implemented everywhere, particularly in low- and middle-income countries and deprived parts of high-income countries.[26,27]

5. Support urgent measures to achieve global vaccine equity, including vaccine sharing, suspension of vaccine patents, removal of barriers to technology transfer, and establish regional production centres to create a plentiful local supply of high-quality vaccines everywhere.[28] Global vaccine rollout should include coordinated efforts to tackle misinformation to ensure people have access to timely, accurate data on vaccine effectiveness and protection.

Vaccines-plus is affordable and achievable. It is the policy advocated by WHO Director General, Dr Tedros Adhanom Ghebreyesus in his statement of 14 December 2021: *“I need to be very clear: vaccines alone will not get any country out of this crisis. Countries can and must prevent the spread of Omicron with measures that work today. It’s not vaccines instead of masks, it’s not vaccines instead of distancing, it’s not vaccines instead of ventilation or hand hygiene. Do it all. Do it consistently. Do it well.”*

References

1. United Kingdom Health Security Agency. Omicron Daily Overview, 20 December 2021. London: UKHSA 2021.
2. Kočańczyk M, Lipniacki T. Pareto-based evaluation of national responses to COVID-19 pandemic shows that saving lives and protecting economy are non-trade-off objectives. *Scientific reports* 2021;11(1):1-9.
3. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. *Immunity* 2020;52(5):737-41. doi: 10.1016/j.immuni.2020.04.012 [published Online First: 2020/05/21]

4. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. *bioRxiv* 2021
5. Fisman D, Tuite A. Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada, February to June, 2021. *medRxiv* 2021
6. Jazieh AR, Kozlakidis Z. Healthcare transformation in the post-coronavirus pandemic era. *Frontiers in Medicine* 2020;7:429.
7. Giattino C, Ritchie H, Roser M, et al. Excess mortality during the Coronavirus pandemic (COVID-19). *Our World in Data* 2021 Updated 13th December 2021. (accessed 21st December 2021).
8. Wu S, Neill R, De Foo C, et al. Aggressive containment, suppression, and mitigation of covid-19: lessons learnt from eight countries. *bmj* 2021;375
9. McCann P, Ortega-Argilés R, Yuan P-Y. The Covid-19 shock in European regions. *Regional Studies* 2021:1-19.
10. Kung S, Doppen M, Black M, et al. Reduced mortality in New Zealand during the COVID-19 pandemic. *Lancet* 2021;397(10268):25. doi: 10.1016/s0140-6736(20)32647-7 [published Online First: 2020/12/18]
11. Olliu-Barton M, Pradelski BSR, Aghion P, et al. SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties. *Lancet* 2021;397(10291):2234-36. doi: 10.1016/s0140-6736(21)00978-8 [published Online First: 2021/05/02]
12. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nature medicine* 2021;27(4):626-31.
13. Ledford H. Do vaccines protect against long COVID? What the data say. *Nature* 2021;599(7886):546-48. doi: 10.1038/d41586-021-03495-2 [published Online First: 2021/11/25]
14. Engzell P, Frey A, Verhagen MD. Learning loss due to school closures during the COVID-19 pandemic. *Proc Natl Acad Sci U S A* 2021;118(17) doi: 10.1073/pnas.2022376118 [published Online First: 2021/04/09]
15. McKee M, Pagel C, Gurdasani D. The NHS is complex, and that's why we should be worried *BMJ* 2021; 375 :n3128 doi:10.1136/bmj.n3128

16. COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December 2021, World Health Organisation
17. WHO recommendations on mask use by health workers, in light of the Omicron variant of concern: WHO interim guidelines, 22 December 2021
18. Morawska L, Milton DK. It is time to address airborne transmission of coronavirus disease 2019 (COVID-19). *Clinical Infectious Diseases* 2020;71(9):2311-13.
19. Greenhalgh T, Ozbilgin M, Contandriopoulos D. Orthodoxy, illusion, and playing the scientific game: a Bourdieusian analysis of infection control science in the COVID-19 pandemic. *Wellcome Open Research* 2021;6(126) doi: 10.12688/wellcomeopenres.16855.1
20. (US) CfDCaP. Science Brief: Community Use of Masks to Control the Spread of SARS-CoV-2. Atlanta: CDC 2021
21. Bagheri G, Thiede B, Hejazi B, et al. An upper bound on one-to-one exposure to infectious human respiratory particles. *Proceedings of the National Academy of Sciences* 2021;118(49):e2110117118. doi: 10.1073/pnas.2110117118
22. Ferris M, Ferris R, Workman C, et al. FFP3 respirators protect healthcare workers against infection with SARS-CoV-2. *Authorea Preprints* 2021
23. Morawska L, Allen J, Bahnfleth W, et al. A paradigm shift to combat indoor respiratory infection. *Science* 2021;372(6543):689-91. doi: 10.1126/science.abg2025
24. Berry G, Parsons A, Morgan M, et al. A review of methods to reduce the probability of the airborne spread of COVID-19 in ventilation systems and enclosed spaces. *Environ Res* 2022;203:111765. doi: 10.1016/j.envres.2021.111765 [published Online First: 2021/08/01]
25. Gettings J, Czarnik M, Morris E, et al. Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools - Georgia, November 16-December 11, 2020. *MMWR Morb Mortal Wkly Rep* 2021;70(21):779-84. doi: 10.15585/mmwr.mm7021e1 [published Online First: 2021/05/28]

26. Cevik M, Baral SD, Crozier A, et al. Support for self-isolation is critical in covid-19 response: British Medical Journal Publishing Group, 2021.
27. Patel J, Fernandes G, Sridhar D. How can we improve self-isolation and quarantine for covid-19? *bmj* 2021;372
28. Katz IT, Weintraub R, Bekker L-G, et al. From Vaccine Nationalism to Vaccine Equity—Finding a Path Forward. *New England Journal of Medicine* 2021;384(14):1281-83.

SIGNATORIES

1. **Trisha Greenhalgh** - Nuffield Department of Primary Care Health Sciences, University of Oxford, UK
2. **Stephen Griffin** - Leeds Institute of Medical Research, School of Medicine, University of Leeds, UK
3. **Deepti Gurdasani** - Queen Mary University of London, UK
4. **Adam Hamdy** - Independent researcher, Mauritius
5. **Aris Katzourakis** - Department of Zoology, University of Oxford, UK
6. **Martin McKee** - London School of Hygiene & Tropical Medicine, UK
7. **Susan Michie** - Department of Clinical, Health and Educational Psychology, University College London, UK
8. **Christina Pagel** - University College London, UK
9. **Alice Roberts** - Professor of Public Engagement in Science, University of Birmingham, UK
10. **Kit Yates** - Centre for Mathematical Biology, Department of Mathematical Sciences, University of Bath, UK

On Behalf of:

11. **World Federation of Public Health Associations**, signing in an institutional capacity
12. **Nisreen Alwan** - Associate Professor of Public Health, University of Southampton, UK
13. **Raymond Agius** - Emeritus Professor of Occupational and Environmental Medicine, The University of Manchester, UK
14. **Haitham Ahmed** - AdvantageCare Physicians, New York, USA
15. **Simon Ashworth** - Clinical Director Critical Care, Imperial College Healthcare NHS Trust, UK
16. **Charlotte Augst** - Chief Executive, National Voices, UK
17. **Simon L. Bacon** - Chair in Innovative, Patient-Oriented, Behavioural Clinical Trials; FRQS co-Chair in Artificial Intelligence and Digital Health for Health

Behaviour Change; Professor, Department of Health, Kinesiology, and Applied Physiology (HKAP), Concordia University; Co-Director, Montreal Behavioural Medicine Centre, CIUSSS-NIM; Co-Lead, International Behavioural Trials Network, Canada

18. **Emil J. Bergholtz** - Department of Physics, Stockholm University, Sweden
19. **David Blanchflower** - Bruce V Rauner Professor of Economics, Dartmouth College and University of Glasgow, UK
20. **Arnold Bosman** - Director Transmissible BV; Former Head of European Programme for Intervention Epidemiology Training at the European Centre for Disease Prevention and Control, Netherlands
21. **Nissaf Bouafif ép Ben Alaya** - Director General, National Observatory of New and Emerging Diseases, Ministry of Health; Head of Department of Preventive Medicine, Faculty of Medicine of Tunis, University Tunis El Manar, Tunisia
22. **Katherine Brown** - Consultant in Paediatric ICU, Great Ormond Street Hospital and Associate Professor University College London, UK
23. **Matthew Butler** - Consultant Geriatrician, Cambridge University Hospitals, UK
24. **Molly Byrne** - Health Behaviour Change Research Group, School of Psychology, National University of Ireland, Galway, Ireland
25. **Roberto Cacciola** - Department of Surgical Sciences, University of Tor Vergata, Rome, Italy
26. **Danielle J. Cane** - London School of Hygiene and Tropical Medicine, London, UK
27. **Fidelia Cascini** - Dipartimento di Scienze della vita e sanità pubblica, Catholic University of the Sacred Heart, Rome, Italy
28. **Mohamed Chahed** - Professor of Epidemiology and Public Health, Faculty of Medicine of Tunis, University Tunis El Manar, Tunisia
29. **KK Cheng** - Director, Institute of Applied Health Research, University of Birmingham, UK
30. **Anthony Costello** - Institute of Global Health, University College London, UK

31. **Andrew Conway Morris** - MRC Clinician Scientist, University of Cambridge;
Hon Consultant in Intensive Care Medicine Addenbrookes Hospital, Cambridge;
Chair, Infection Section, European Society of Intensive Care Medicine, UK
32. **Roz Davies** - Managing Director, Thrive by Design, UK
33. **Colin Davis** - School of Psychological Science, University of Bristol, UK
34. **Brendan Delaney** - Professor of Medical Informatics and Decision Making,
Imperial College, London, UK
35. **Denise Dewald** - Case Western Reserve University School of Medicine,
Cleveland, Ohio, USA
36. **David Drew** - retired NHS Consultant Paediatrician, UK
37. **John Drury** - School of Psychology, University of Sussex, UK
38. **Andrew Ewing** - Department of Chemistry and Molecular Biology, University of
Gothenburg; Swedish Academy of Sciences, Sweden
39. **David Fisman** - Professor of Epidemiology, Dalla Lana School of Public Health,
University of Toronto, Toronto, ON, Canada
40. **Sharon Friel** - ARC Laureate Fellow and Professor of Health Equity, Australian
National University, Australia
41. **Malgorzata Gasperowicz** - Faculty of Nursing, University of Calgary, Canada
42. **David Robert Grimes** - Dublin City University and University of Oxford, Ireland
43. **Zubaida Haque** - Independent SAGE, UK
44. **William A Haseltine** - Chair and President ACCESS Health International, USA
45. **Orla Hegarty** - School of Architecture, Planning & Environmental Policy,
University College Dublin, Ireland
46. **Simon Hodes** - GP Partner & Covid Vaccinator, Bridgewater Surgeries, Watford
and Cleveland Clinic London, UK
47. **Eilir Hughes** - General Practitioner, West Wales, UK
48. **Zoë Hyde** - Research Fellow, Western Australian Centre for Health and Ageing,
The University of Western Australia, Australia
49. **Lisa Iannattone** - Assistant Professor, University of Montreal, Canada
50. **Alejandro R. Jadad** - Founder, Centre for Global eHealth Innovation, Chairman,
Beati Inc., Toronto, Canada

51. **Neena Jha** - General Practitioner, Hertfordshire, UK
52. **Jose Luis Jimenez** - Professor, Department of Chemistry and Cooperative Institute for Research in the Environmental Sciences, University of Colorado, Boulder, CO, USA
53. **John Johnson** - Emergency Physician, Eastern Health, Melbourne, Australia.
54. **Abraar Karan** - Division of Infectious Diseases & Geographic Medicine, Stanford University, USA
55. **Kamlesh Khunti** - Professor of Primary Care Diabetes and Vascular Medicine, University of Leicester, UK
56. **Najwa Khuri-Bulos** - Distinguished Professor of Pediatrics and Infectious Diseases, University of Jordan; Adjunct Professor, Pediatric Infectious Disease, Vanderbilt University, Nashville, USA
57. **Woo Joo Kim** - Professor, Division of Infectious Diseases, Guro Hospital; Director, Chung Mong-koo Vaccine Innovation Center, College of Medicine, Korea University, Seoul, Republic of Korea
58. **Matthew J Knight** - Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust, UK
59. **Kim L. Lavoie** - Canada Research Chair in Behavioural Medicine, Professor, Department of Psychology, University of Quebec at Montreal; Co-Director, Montreal Behavioural Medicine Centre, Centre intégré de santé et de services sociaux de Nord de l'Île de Montreal (CIUSSS-NIM); Member, Canadian COVID-19 Expert Panel, Canada
60. **Tom Lawton MBE** - Bradford Institute for Health Research; Bradford Teaching Hospitals NHS Foundation Trust, UK
61. **Jeffrey V Lazarus** - Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Spain.
62. **Anthony Joseph Leonardi** - Johns Hopkins University Bloomberg School of Public Health, USA
63. **Eyal Leshem** - Director of the Center for Travel Medicine and Tropical Diseases, Sheba Medical Center; Associate Professor, Tel Aviv University School of Medicine, Israel

64. **Liz Lightstone** - Professor, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London and Co-chair, COVID Treatment and Guideline Group, Imperial College Healthcare NHS Trust, London, UK
65. **Peter V. Markov** - London School of Hygiene & Tropical Medicine, London, UK
66. **Jose M Martin-Moreno** - Department of Preventive Medicine and Public Health & INCLIVA, University of Valencia, Spain
67. **Petra Meier** - Professor of Public Health and MRC Investigator; Programme lead Systems Science in Public Health; Director, SIPHER Consortium, MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, UK
68. **Jonathan Mesiano-Crookston** - Partner Goldman Hine LLP, Canada
69. **Asit Kumar Mishra** - Postdoctoral Researcher, Sustainable & Resilient Structures Research Group, NUI Galway, Ireland
70. **Michael Moore** - Distinguished Fellow The George Institute for Global Health, Adjunct Professor Uni of Canberra, Past President World Federation of Public Health Associations, Australia
71. **Sterghios A. Moschos** - Associate Professor, Cellular and Molecular sciences Northumbria University, UK
72. **C David Naylor** - Professor of Medicine, University of Toronto, Toronto, Canada
73. **Taylor Nichols** - Emergency Medicine Physician, Sacramento, USA
74. **David Nicholl** - Clinical Lead for Neurology, Sandwell & West Birmingham NHS Trust, UK
75. **Ole F. Norheim** - Director, BCEPS, Department of Global Public Health and Primary Care, University of Bergen, Norway
76. **Matthew Oliver** - Association of Professional Engineers and Geoscientists of Alberta, Edmonton, Alberta, Canada.
77. **Christine Peters** - Clinical Lead Consultant Microbiologist, QEUH NHS Greater Glasgow and Clyde, UK
78. **Deenan Pillay** - Professor of Virology, University College London, UK
79. **Dominic Pimenta** - Richmond Research Institute, UK
80. **Kashif Pirzada** - Emergency Physician and Assistant Clinical Professor of Medicine (Adj), McMaster University, Canada

81. **Catherine Pope** - Professor of Medical Sociology, University of Oxford, UK
82. **Kimberly A Prather** - Professor, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA, USA
83. **Geraint Preest** - General Practitioner, Pencoed, Wales, UK
84. **Zeshan Quereshi** - University of Cambridge, UK
85. **Katrin Rabiei** - Institution of Neuroscience & Physiology, Sahlgrenska Academy at Gothenburg University, Sweden
86. **James Ray** - Urgent and Emergency Care Regional Lead, NHS England, UK
87. **K. Srinath Reddy** - President, Public Health Foundation of India, India
88. **Walter Ricciardi** - Università Cattolica del Sacro Cuore Roma, Italy
89. **Ken Rice** - School of Physics and Astronomy, University of Edinburgh, UK
90. **Eleanor Robertson** - Senior Clinical Research Fellow, NHS Greater Glasgow and Clyde, UK
91. **Kim Roberts** - Department of Microbiology, Trinity College Dublin, Ireland.
92. **Tomás Ryan** - Associate Professor, Trinity College Dublin, Ireland
93. **Helen Salisbury** - Nuffield Dept of Primary Care Health Sciences, University of Oxford, UK
94. **Gabriel Scally** - Population Sciences, University of Bristol, UK
95. **Robert T. Schooley** - Distinguished Professor of Medicine, University of California San Diego, USA
96. **Vipul Shah** - R P Shah Memorial Trust, Lucknow, India
97. **Joshua Silver** - Department of Physics, University of Oxford, UK
98. **Natalie Silvey** - Anaesthetic Registrar, Imperial School of Anaesthesia, London, UK
99. **Manoj Sivan** - Associate Professor and Consultant in Rehabilitation Medicine, University of Leeds and Leeds Teaching Hospitals NHS Trust, UK
100. **Luis Eugenio Souza** - Federal University of Bahia; World Federation of Public Health Associations, Brazil
101. **Anthony Staines** - Professor of Health systems, School of Nursing, Psychotherapy and Community Health, Dublin City University, Ireland

102. **David Tomlinson** - Consultant Cardiologist and Electrophysiologist, University Hospitals Plymouth NHS Trust & Fresh Air NHS, UK
103. **Collin Tukuitonga** - Associate Dean (Pacific) and Associate professor of Public Health, Faculty of Medical and Health Sciences, University of Auckland, New Zealand
104. **Charles Vincent** - Professor of Psychology, University of Oxford, Oxford, UK
105. **Joe Vipond** - Clinical Assistant Professor, University of Calgary, Canada
106. **Robert West** - Professor Emeritus of Health Psychology, Institute of Epidemiology and Healthcare, University College London, UK
107. **Angela C. Weyand** - University of Michigan Medical School, Ann Arbor, MI, USA
108. **Hisham Ziauddeen** - Department of Psychiatry, University of Cambridge, Cambridge; Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge; Cambridgeshire & Peterborough Foundation Trust, Cambridge, UK